- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Prime Medicine Inc (PRME)
Prime Medicine Inc stock price live, this page displays NASDAQ PRME stock exchange data. View the PRME premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Prime Medicine Inc real time stock price chart below.
What Is the Prime Medicine Inc Stock Price Today?
The Prime Medicine Inc stock price today is 3.390.
What Is the Stock Symbol for Prime Medicine Inc?
The stock symbol for Prime Medicine Inc is "PRME."
What Stock Exchange Does Prime Medicine Inc Trade On?
Prime Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Prime Medicine Inc a Good Stock to Buy?
Determining whether Prime Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRME quote. (ISIN: US74168J1016)
What Is the Prime Medicine Inc Stock Price Today?
The Prime Medicine Inc stock price today is 3.390.
What Is the Stock Symbol for Prime Medicine Inc?
The stock symbol for Prime Medicine Inc is "PRME."
What Stock Exchange Does Prime Medicine Inc Trade On?
Prime Medicine Inc is listed and trades on the NASDAQ stock exchange.
Is Prime Medicine Inc a Good Stock to Buy?
Determining whether Prime Medicine Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PRME quote. (ISIN: US74168J1016)
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.240
3.490
52 wk Range
2.670
6.940
PRME is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
3.2403.490
52 wk Range
2.6706.940
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PRME Scorecard
Company’s Health
Assesses a company's financial position by analyzing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
7.295
Upside
+115.21%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Analyst Ratings
10 Buy
3 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 7.295
(+115.21% Upside)
Earnings
Latest Release
Aug 06, 2026
EPS / Forecast
-0.24 / -0.36
Revenue / Forecast
1.15M / --
Compare PRME to Peers and Sector
Metrics to compare | PRME | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPRMEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −3.2x | −1.5x | −0.4x | |
PEG Ratio | −0.10 | −0.05 | 0.00 | |
Price/Book | 15.1x | 2.6x | 2.6x | |
Price / LTM Sales | 148.1x | 134.8x | 3.1x | |
Upside (Analyst Target) | 136.0% | 143.9% | 48.9% | |
Fair Value Upside | Unlock | 16.9% | 6.2% | Unlock |
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic medicines to address the spectrum of diseases by deploying gene editing technology in the United States. Its lead therapeutic product candidate is PM359 for Chronic Granulomatous Disease, which is in Phase 1/2 clinical trial; PM577 for Wilson Disease, that is in preclinical studies; and PM647 to treat genetic disorder caused by mutations in the SERPINA1 gene, resulting in production of misfolded Z-AAT protein that accumulates in the liver and leads to hepatocellular injury, cirrhosis, and increased risk of hepatocellular carcinoma. The company also provides vivo programs targeting diseases of the liver, and Cystic Fibrosis programs. In addition, it offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration and license agreement with BMS; Cystic Fibrosis Foundation; Broad Institute; and Beam. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Prime Medicine (PRME) Stock Price Today?
The Prime Medicine stock price today is 3.390 USD.
What Stock Exchange Does Prime Medicine Trade On?
Prime Medicine is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Prime Medicine?
The stock symbol for Prime Medicine is "PRME."
What Is the Prime Medicine Market Cap?
As of today, Prime Medicine market cap is 603.100M USD.
What Is Prime Medicine's Earnings Per Share (TTM)?
The Prime Medicine EPS (TTM) is -1.085.
When Is the Next Prime Medicine Earnings Date?
Prime Medicine will release its next earnings report on Oct 30, 2026.
From a Technical Analysis Perspective, Is PRME a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Prime Medicine Stock Split?
Prime Medicine has split 0 times.
How Many Employees Does Prime Medicine Have?
Prime Medicine has 146 employees.
What is the current trading status of Prime Medicine (PRME)?
As of Aug 23, 2026, Prime Medicine (PRME) is trading at a price of 3.390 USD, with a previous close of 3.240 USD. The stock has fluctuated within a day range of 3.240 USD to 3.490 USD, while its 52-week range spans from 2.670 USD to 6.940 USD.
What Is Prime Medicine (PRME) Price Target According to Analysts?
The average 12-month price target for Prime Medicine is 7.295 USD, with a high estimate of 11 USD and a low estimate of 4.25 USD. 10 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +115.21% Upside potential.
What Is the PRME Premarket Price?
PRME's last pre-market stock price is 3.260 USD. The pre-market share volume is 19,600.000, and the stock has decreased by 0.020, or 0.620%.
What Is the PRME After Hours Price?
PRME's last after hours stock price is 3.450 USD, the stock has decreased by 0.060, or 1.770%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.